Myriad Genetics Inc reports results for the quarter ended March 31 - Earnings Summary
I'm PortAI, I can summarize articles.
Myriad Genetics Inc reported a quarterly adjusted loss of 3 cents per share for the quarter ended March 31, an improvement from a loss of 1 cent per share in the same quarter last year. Revenue decreased by 3.1% to $195.90 million, below analyst expectations of $200.56 million. The company reported a quarterly loss of $100 thousand and its shares fell by 13.2% this quarter. Analysts maintain a "hold" rating on the stock, with a median 12-month price target of $14.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments